Reading Paige’s Playbook For Cancer Diagnostics

Paige CEO Andy Moye talked to Medtech Insight about the company’s current offerings in the prostate and breast cancer markets, as well as its future ambitions and general strategy.

Paige has been developing algorithms that can detect indiscernible-to-the-eye differences in hematoxylin and eosin-stained (H&E) biopsy slides, aiding doctors in the diagnosis of cancer.

The company has had a frantic past four years

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from AI

More from Digital Technologies